Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 13/20 | 0.68 |
| ▸ | PLAU | P00749 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983493 | 0.90 | NR1H4 (0.65) | NR1H4PLAUKDM4EALDH1A1GAA | |
| SCHEMBL2977922 | 0.86 | GAA (0.62) | NR1H4PLAUATMKDM4EALDH1A1 | |
| SCHEMBL2988806 | 0.86 | NR1H4 (0.80) | NR1H4GAAMAPT | |
| SCHEMBL2992416 | 0.85 | KDM4E (0.66) | NR1H4PLAUKDM4EALDH1A1GAA | |
| SCHEMBL2986724 | 0.84 | NR1H4 (0.58) | NR1H4PLAUATMKDM4EALDH1A1 | |
| SCHEMBL2990539 | 0.83 | NR1H4 (0.57) | NR1H4PLAUKDM4EALDH1A1GAA | |
| SCHEMBL2984269 | 0.81 | NR1H4 (0.72) | NR1H4ATMKDM4EALDH1A1GAA | |
| SCHEMBL2987066 | 0.78 | KDM4E (0.69) | NR1H4PLAUKDM4EALDH1A1GAA | |
| SCHEMBL2982973 | 0.77 | ALDH1A1 (0.68) | NR1H4ATMKDM4EALDH1A1GAA | |
| SCHEMBL2987957 | 0.76 | ALDH1A1 (0.54) | NR1H4PLAUATMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-07-08 | — | — | US | claimed |
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC. | 2010-07-08 | — | — | US | disclosed |
| WO-2008016648-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173930-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | NR1H4 4747/4885PLAU 2493/4885ATM 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.